Arsenic Trioxide in Synergy with Vitamin D Rescues the Defective VDR-PPAR-γ Functional Module of Autophagy in Rheumatoid Arthritis.
Weiyan WangChunling LiZhiyi ZhangYue ZhangPublished in: PPAR research (2019)
Dysregulated autophagy leads to autoimmune diseases including rheumatoid arthritis (RA). Arsenic trioxide (ATO) is a single agent used for the treatment of acute promyelocytic leukemia and is highly promising for other malignancies but is also attractive for RA, although its relationship with autophagy remains to be further clarified and its application optimized. For the first time, we report a defective functional module of autophagy comprising the Vitamin D receptor (VDR), PPAR-γ, microtubule-associated protein 1 light-chain 3 (LC3), and p62 which appears in RA synovial fibroblasts. ATO alleviated RA symptoms by boosting effective autophagic flux through significantly downregulating p62, the inflammation and catabolism protein. Importantly, low-dose ATO synergizes with Vitamin D in RA treatment.
Keyphrases
- rheumatoid arthritis
- cell death
- disease activity
- oxidative stress
- ankylosing spondylitis
- endoplasmic reticulum stress
- low dose
- signaling pathway
- interstitial lung disease
- systemic lupus erythematosus
- drinking water
- heavy metals
- insulin resistance
- acute myeloid leukemia
- metabolic syndrome
- mass spectrometry
- type diabetes
- bone marrow
- mouse model
- fatty acid
- intensive care unit
- extracellular matrix
- skeletal muscle
- high resolution
- small molecule
- risk assessment
- depressive symptoms
- acute respiratory distress syndrome
- simultaneous determination
- liquid chromatography
- replacement therapy